Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure

被引：0
|
作者：
Min Weng
Wei-Zheng Zeng
Xiao-Ling Wu
Yong Zhang
Ming-De Jiang
Zhao Wang
De-Jiang Zhou
Xuan He
机构：
[1] General Hospital of Chengdu Military Region of PLA,Department of Digestion
来源：
Virology Journal | / 10卷
关键词：
Chronic hepatitis B; Lamivudine exposure; Pegylated interferon α-2a; Hepatitis B surface antigen quantification; Predictability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure
    Weng, Min
    Zeng, Wei-Zheng
    Wu, Xiao-Ling
    Zhang, Yong
    Jiang, Ming-De
    Wang, Zhao
    Zhou, De-Jiang
    He, Xuan
    VIROLOGY JOURNAL, 2013, 10
  • [2] Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    Lau, GKK
    Piratvisuth, T
    Luo, KX
    Marcellin, P
    Thongsawat, S
    Cooksley, G
    Gane, E
    Fried, MW
    Chow, WC
    Paik, SW
    Chang, WY
    Berg, T
    Flisiak, R
    McCloud, P
    Pluck, N
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (26): : 2682 - 2695
  • [3] Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised
    Janssen, HLA
    van Zonneveld, M
    Senturk, H
    Zeuzem, S
    Akarca, US
    Cakaloglu, Y
    Simon, C
    So, TMJ
    Gerken, G
    de Man, RA
    Niesters, HGM
    Zondervan, P
    Hansen, B
    Schalm, SW
    LANCET, 2005, 365 (9454): : 123 - 129
  • [4] A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B
    Chan, H. L. Y.
    Messinger, D.
    Papatheodoridis, G. V.
    Cornberg, M.
    Xie, Q.
    Piratvisuth, T.
    Ren, H.
    Kennedy, P. T.
    Thompson, A.
    Caputo, A.
    Bakalos, G.
    Pavlovic, V.
    Lampertico, P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (05) : 547 - 555
  • [5] Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B
    van Boemmel, Florian
    van Boemmel, Alena
    Krauel, Alexander
    Wat, Cynthia
    Pavlovic, Vedran
    Yang, Lei
    Deichsel, Danilo
    Berg, Thomas
    Boehm, Stephan
    JOURNAL OF INFECTIOUS DISEASES, 2018, 218 (07): : 1066 - 1074
  • [6] Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B
    Chuaypen, Natthaya
    Posuwan, Nawarat
    Payungporn, Sunchai
    Tanaka, Yasuhito
    Shinkai, Noboru
    Poovorawan, Yong
    Tangkijvanich, Pisit
    LIVER INTERNATIONAL, 2016, 36 (06) : 827 - 836
  • [7] Predicting response to peginterferon alfa-2a (40 KD) (PEGASYS®) in Asian patients with HBeAg-positive chronic hepatitis B
    Cooksley, Graham
    Chow, Wan Cheng
    Piratvisuth, Teerha
    Lau, George K. K.
    Mccloud, Philip
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A108 - A108
  • [8] PREDICTORS OF DEVELOPMENT OF HBEAG-NEGATIVE CHRONIC HEPATITIS B FOLLOWING PEGINTERFERON ALFA-2A THERAPY IN HBEAG-POSITIVE CHRONIC HEPATITIS B
    Peng, Cheng-Yuan
    Shih, Chao-Jen
    Lo, Pei-Shuan
    Huang, Chia-Lin
    Lai, Hsueh-Chou
    Su, Wen-Pang
    Chuang, Po-Heng
    Kao, Jung-Ta
    HEPATOLOGY, 2011, 54 : 1027A - 1028A
  • [9] HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
    Fried, Michael W.
    Piratvisuth, Teerha
    Lau, George K. K.
    Marcellin, Patrick
    Chow, Wan-Cheng
    Cooksley, Graham
    Luo, Kang-Xian
    Paik, Seung Woon
    Liaw, Yun-Fan
    Button, Peter
    Popescu, Matei
    HEPATOLOGY, 2008, 47 (02) : 428 - 434
  • [10] Hepatitis B core-related antigen levels predict pegylated interferon-α therapy response in HBeAg-positive chronic hepatitis B
    Beudeker, Boris J. B.
    Groothuismink, Zwier M. A.
    de Man, Robert A.
    Janssen, Harry L. A.
    van der Eijk, Annemiek A.
    Boonstra, Andre
    Sonneveld, Milan J.
    ANTIVIRAL THERAPY, 2020, 25 (04) : 217 - 222
12345